Food and Drug Administration first approved Trulicity as a treatment for Type 2 diabetes
Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ et al (2024) Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
If muscle symptoms are severe or persistent despite these interventions, clinicians should consider laboratory evaluation including creatine kinase, comprehensive metabolic panel with separate magnesium and calcium testing, thyroid function tests, vitamin D levels, and vitamin B12 levels to exclude alternative diagnoses
Bankroll planning is easier when the cashier and the bet slip work together